StockMacro
Menu

20/20 Biolabs

$0.16 -85% in 6 monthsMarket cap $2.2M

AIDX on XNAS, Services, 20/20 Biolabs, Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 84% in six months after a delisting notice while a $6.4M net loss on $2M revenue.

  • BadGross margin 30% but operating margin -249% on $2M revenue

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

Industry
Services-testing laboratories (Services)
Employees
14
Website
2020biolabs.com
Listed
Nasdaq, US
Last results
16 Nov 2026
Next results
expected around 30 Mar 2027 (an estimate: a year ago it reported on 31 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $380K, net loss $1.4M.
Quarter to 31 Mar 2025: revenue $554K, net income -$765KQuarter to 31 Mar 2025: revenue $554K, net income -$765KQuarter to 30 Jun 2025: revenue $535K, net income -$841KQuarter to 30 Jun 2025: revenue $535K, net income -$841KQuarter to 30 Sep 2025: revenue $418K, net income -$826KQuarter to 30 Sep 2025: revenue $418K, net income -$826KQuarter to 31 Dec 2025: revenue $538K, net income -$1.3MQuarter to 31 Dec 2025: revenue $538K, net income -$1.3MQuarter to 31 Mar 2026: revenue $353K, net income -$2.2MQuarter to 31 Mar 2026: revenue $353K, net income -$2.2MQuarter to 30 Jun 2026: revenue $731K, net income -$1.5MQuarter to 30 Jun 2026: revenue $731K, net income -$1.5MQuarter to 30 Sep 2026: revenue $380K, net income -$1.4MQuarter to 30 Sep 2026: revenue $380K, net income -$1.4M
31 Mar 2025RevenueNet incomeNet losstallest bar $2.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$380K-$1.4M
30 Jun 2026$731K-$1.5M
31 Mar 2026$353K-$2.2M
31 Dec 2025$538K-$1.3M
30 Sep 2025$418K-$826K
30 Jun 2025$535K-$841K
31 Mar 2025$554K-$765K
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $2.0M –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +5.8%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$6.4M –
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 29.7% – 38.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -249% – 6.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -318% – 2.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – 8.7%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $3.6M $1.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.77
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.04
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 23.9
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.1 1.2
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 1.6
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.6 2.3

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
20/20 BiolabsAIDX (this company) $2.2Mloss1.1–-318%
OFAOFAL $1.9Mloss–––
Arrive AIARAI $1.7Mloss20.5––
Kustom EntertainmentKUST $1.7Mloss0.09+52%-72.9%
Callan JMBCJMB $3.2Mloss0.67-19%-204%
Treasure GlobalTGL $3.6Mloss0.49+212%-99.5%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

3.9%

541K shares held by 13F filers (30 Sep 2026) of 14.0M outstanding (13 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.4%

57K shares sold short (30 Oct 2026) of 14.0M outstanding (13 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

57K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+406%

11K shares sold short in the report before, 57K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

27%

27% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 30%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

9

9 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

9.0×

9 articles in the last 7 days; its usual week has 1.

Price $0.16 on 20 Nov 2026, -99% over 12 months (12-month range $0.16 to $23.85)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Revenue per quarter. Revenue $380K in the latest quarter, -9.0% on a year earlier.
Institutional holders (13F filers). 16 13F filers reported holding it in the latest 13F quarter, +129% on a year earlier.
Lobbying spend. Lobbying spend: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: insider net buying (open market), h-1b/e-3 applications certified, capital spending per quarter, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
10 Sep 20268-K and other filingsDelisting notice or listing transfer
22 Jul 20268-K and other filingsDelisting notice or listing transfer
15 May 20268-K and other filingsReport will be filed late
6 Apr 20268-K and other filingsRegistered new securities for sale (S-1)
26 Jan 20268-K and other filingsRegistered new securities for sale (S-1)
21 Jan 20268-K and other filingsRegistered new securities for sale (S-1)
12 Dec 20258-K and other filingsRegistered new securities for sale (S-1)
26 Feb 20258-K and other filingsPrivate placement of securities (Form D)
2 Oct 2023Lobbying filinglobbying engagement terminated (JD LISS ASSOCIATES FORMERLY KNOWN AS JONATHAN DAVID LISS)
20 Mar 2023Lobbying filingnew lobbying registration (JD LISS ASSOCIATES FORMERLY KNOWN AS JONATHAN DAVID LISS)
20 Mar 2023Sharp changeFirst lobbying registration: first lobbying registration: 20/20GENE SYSTEMS: new lobbying registration (JD LISS ASSOCIATES FORMERLY KNOWN AS JONATHAN DAVID LISS)
Revenue per quarter
Quarter ended 31 Mar 2025: $554K; public on 21 May 2026
Quarter ended 30 Jun 2025: $535K; public on 15 Aug 2026
Quarter ended 30 Sep 2025: $418K; public on 17 Nov 2026
Quarter ended 31 Dec 2025: $538K; public on 1 Apr 2026
Quarter ended 31 Mar 2026: $353K, -36% on a year earlier; public on 21 May 2026
Quarter ended 30 Jun 2026: $731K, +37% on a year earlier; public on 15 Aug 2026
Quarter ended 30 Sep 2026: $380K, -9.0% on a year earlier; public on 17 Nov 2026
Institutional holders (13F filers)
31 Mar 2026 report: 7; public on 15 May 2026
30 Jun 2026 report: 15; public on 14 Aug 2026
30 Sep 2026 report: 16; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2023: $8K published
Quarter from 1 Jul 2023: $26K published
Quarter from 1 Oct 2023: $26K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is short interest change vs previous settlement, % (as published by FINRA) at 406 (30 Oct 2026), 2038% below its normal reading of -20.9; higher than 94% of its own history.
  • Revenue per quarter: Revenue $380K in the latest quarter, -9.0% on a year earlier.
  • Institutional holders (13F filers): 16 13F filers reported holding it in the latest 13F quarter, +129% on a year earlier.
  • Lobbying spend: Lobbying spend: $0 published in the last 12 months.

Latest records

The names and amounts behind the totals, newest first

16 institutions reported shares at the end of Q3 2026, 4% of the shares outstanding; 3 opened a position, 2 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Cresset Asset Management, LLC240K1.72%$105KNo change
Citadel Advisors LLC64K0.46%$28K+41K+175%
Geode Capital Management, LLC54K0.39%$24K+5,352+11%
Vanguard Fiduciary Trust Co52K0.37%$23KNo change
Atlantic Union Bankshares Corp35K0.25%$15KNo change
XTX Topco Ltd33K0.23%$14KNew+33K
Vanguard Capital Management LLC30K0.21%$13K+5,000+20%
HRT Financial LP15K0.11%-74K-83%
Bank of America Corp13K0.09%$6K+115+0.9%
McDonald Partners LLC2,8000.02%$1KNo change

Company events

All 11 company events

In 12 months: 4 share registrations, 2 major agreements, 2 delisting notices, 1 late report. Results releases and routine reports are left out.

FiledWhat happenedSource
10 Sep 2026Delisting notice or listing transfer8-K
22 Jul 2026Signed a major agreement; Delisting notice or listing transfer8-K
15 May 2026Quarterly report will be filed lateNT 10-Q
28 Apr 2026Signed a major agreement8-K
6 Apr 2026Registered new securities for sale (S-1)S-1
26 Jan 2026Registered new securities for sale (S-1)S-1/A
21 Jan 2026Registered new securities for sale (S-1)S-1/A
12 Dec 2025Registered new securities for sale (S-1)S-1

Reported lobbying spend: $26K in Q3 2023, $26K in Q2 2023. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Sep 2023EndedJD Liss Associates Formerly Known As Jonathan David Lissfor 20/20Gene SystemsMulti Cancer Early Detection Legislation seeking Medicare reimbursement for tests that detect multiple cancers earlyHealth issuesFiling
17 Mar 2023NewJD Liss Associates Formerly Known As Jonathan David Lissfor 20/20Gene SystemsMulti-cancer early detection testing legislationHealth issuesFiling

The 5 newest of 44 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 10 Sep 2026Filings record

    Delisting notice or listing transfer

  2. 22 Jul 2026Filings record

    Delisting notice or listing transfer

  3. 15 May 2026Filings record

    Report will be filed late

  4. 6 Apr 2026Filings record

    Registered new securities for sale (S-1)

  5. 26 Jan 2026Filings record

    Registered new securities for sale (S-1)

  6. 21 Jan 2026Filings record

    Registered new securities for sale (S-1)

  7. 12 Dec 2025Filings record

    Registered new securities for sale (S-1)

  8. 26 Feb 2025Filings record

    Private placement of securities (Form D)

  9. 2 Oct 2023Lobbying record

    20/20GENE SYSTEMS: lobbying engagement terminated (JD LISS ASSOCIATES FORMERLY KNOWN AS JONATHAN DAVID LISS) (dated 30 Sep 2023)

  10. 20 Mar 2023Lobbying change

    registered for federal lobbying for the first time in our data (Jd Liss Associates Formerly Known As Jonathan David Liss).

    See the evidence (1 source record)
    Source coverage starts
    2 Jul 2009
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  11. 20 Mar 2023Lobbying record

    20/20GENE SYSTEMS: new lobbying registration (JD LISS ASSOCIATES FORMERLY KNOWN AS JONATHAN DAVID LISS) (dated 17 Mar 2023)

  12. 4 Feb 2016Filings record

    Private placement of securities (Form D)

Not listed: 10 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001139685
Ticker
AIDX
Domain
2020biolabs.com
Hq location
MD|ROCKVILLE|20850 (1 unverified)
Lobbying client
20 20gene systems
Name
20/20 Biolabs, Inc., 20/20 GeneSystems, Inc., 20/20 GENE SYSTEMS INC
  • Federal lobbying disclosures (LDA)2 records, 9 data points17 Mar 2023 to 30 Sep 2023
  • SEC Form 13F institutional holdings27 data points31 Mar 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)19 records4 Feb 2016 to 16 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)116 data points31 Dec 2023 to 13 Nov 2026
  • FINRA short interest (twice monthly)50 data points27 Feb 2026 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)384 data points19 Feb 2026 to 20 Nov 2026